Navigation Links
Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
Date:1/22/2008

Fourth Quarter 2007 Financial Results

VANCOUVER, Jan. 22 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, will host a conference call discussing its financial results for the fourth quarter and year ended December 31, 2007.

Thursday, February 14, 2008 at 11:00 AM ET

(8:00 AM Pacific, 9:00 AM Mountain, 10:00 AM Central)

Dial information is as follows:

North America (toll-free): (866) 510-0711

International: (617) 597-5379

Enter passcode: 91184096

A live webcast will be available to all interested parties through Angiotech's website at http://www.angiotech.com in the Investor Relations section.

A press release announcing Angiotech's financial results will be issued prior to the conference call at approximately 8:00 AM ET (5:00 AM Pacific, 6:00 AM Mountain, 7:00 AM Central).

A replay archive of the conference call will be available until February 21, 2008.

Replay information is as follows:

North America: (888) 286-8010

International: (617) 801-6888

Enter passcode: 85112963

About Angiotech Pharmaceuticals

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX, ANP) please visit our website at http://www.angiotech.com.

CONTACT: Jodi Regts, Senior Manager, Investor Relations and Corporate Communications, Angiotech Pharmaceuticals, Inc., (604) 221-7930, jregts@angio.com; Deirdre Neary, Manager, Investor Relations and Corporate Communications, Angiotech Pharmaceuticals, Inc., (604) 222-7056, dneary@angio.com


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Angiotech and Symphony Medical Announce Licensing Agreement
2. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
3. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
4. Angiotech to participate in RBC 2007 Healthcare Conference
5. Angiotech to participate in Bank of America 2007 Credit Conference
6. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
7. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
8. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
9. Angiotech to participate in UBS Global Life Sciences Conference
10. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
11. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... Advanced Polymer Monitoring Technologies (APMT), ... Sigmund “Sig” Floyd as Vice President ? Global Business Development. Dr. Floyd will ... “Dr. Floyd’s career has spanned 30 years in the chemicals and equipment industries. ...
(Date:3/22/2017)... March 22, 2017 Good Start Genetics, a ... eclipsed the 130 million covered lives mark through its ... Texas . With newly signed contracts ... to enjoy strong payor acceptance based on the quality ... and genetic counseling, its industry-leading customer care and support ...
(Date:3/22/2017)... /PRNewswire/ - FACIT announced a seed stage investment ... start-up created by FACIT focused on developing a ... with non-dilutive capital, achieves a targeted $3.0M financing ... Propellon to accelerate the nomination of a candidate ... entering a strategic partnership for clinical trials in ...
(Date:3/22/2017)... , ... March 21, 2017 , ... ... biologics. To acquire information on the desired increase and/or decrease in antibody-dependent cellular ... for rapid N-glycosylation profiling of therapeutic antibodies. , To meet this demand, ...
Breaking Biology Technology:
(Date:3/2/2017)... 2017 Australian stem cell and regenerative medicine ... signed an agreement with the Monash Lung Biology Network, ... Institute and Department of Pharmacology at Monash University, ... study to support the use of Cymerus™ mesenchymal stem ... Asthma is a chronic, long term lung condition ...
(Date:2/28/2017)... Feb. 28, 2017   Acuant , a leading ... announces significant enhancements to new and core technologies building ... products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity documents ... provides the fastest and most accurate capture software to ...
(Date:2/28/2017)... Spanien, 27. Februar 2017  EyeLock LLC, ein marktführendes ... seine erstklassige biometrische Lösung zur Iris-Erkennung auf ... X16 LTE auf dem Mobile World Congress ... Qualcomm-Stand in Halle 3, Stand 3E10, vorstellen. ... Sicherheitsplattform Qualcomm Haven™ – eine Kombination aus ...
Breaking Biology News(10 mins):